Why It Matters
Alabama’s medical cannabis program is moving into its expansion phase, with a second dispensary location now operational and multiple additional sites expected to open within weeks. The rollout directly affects thousands of registered patients seeking access to cannabis for conditions including cancer, chronic pain, and PTSD, with the program ultimately planned to reach at least 37 locations statewide.
What Happened
Callie’s Apothecary opened its second location in Talladega on Friday, marking accelerated growth for Alabama’s newly operational medical cannabis market. The Montgomery location, which opened in June, preceded this expansion by approximately three months and has already served hundreds of patients since its launch.
The Talladega opening is part of a broader first-round rollout involving four licensed operators. CCS of Alabama LLC, the company operating Callie’s Apothecary, plans to open a third location in Bessemer in September. GP6 Wellness LLC is preparing to launch BamaBloom dispensaries in Athens and Birmingham, also expected in September, with an additional location planned for Etowah County. RJK Holdings LLC has secured licenses for sites in Oxford, Mobile, and Daphne.
The program’s foundation traces back to 2021, when the Alabama Legislature enacted the medical cannabis law. However, the gap between legislative approval and the first patient sale spanned five years, delayed by litigation over licensing procedures and regulatory framework. Despite those delays, patient demand has been rapid: the Montgomery location recorded $15,000 in sales during its first week of operation.
Registered physicians may recommend cannabis for approximately 15 qualifying conditions: cancer, depression, Parkinson’s disease, PTSD, sickle-cell anemia, chronic pain, and terminal illnesses, among others. The state permits only non-smokable forms—tablets, tinctures, patches, oils, and gel cubes (peach flavor only)—with raw plant material and smoking explicitly prohibited.
By the Numbers
12 — dispensaries planned across the four licensed companies in the first operational round
37 — dispensaries anticipated at full program capacity statewide
800 — patients registered at the Montgomery location since June
1,300 — transactions completed at the Montgomery dispensary
15 — medical conditions for which physicians may recommend cannabis
5 years — interval between Legislature approval (2021) and first dispensary opening (June 2026)
Zoom Out
Alabama’s phased launch mirrors the rollout strategy adopted by other states that have legalized medical cannabis. Most programs operate with staggered licensing rounds and geographic distribution requirements designed to balance patient access with regulatory oversight. The initial four-operator framework is not uncommon; many states begin with a limited number of licensed entities and expand after demonstrating compliance and operational capacity.
The emphasis on non-smokable products reflects a regulatory preference increasingly common across U.S. medical cannabis programs. States citing public health rationales have restricted combustible forms in favor of controlled-dosage delivery systems. Alabama’s approach aligns with programs in states including Florida and Ohio, which similarly prohibit raw flower.
What’s Next
Three additional dispensary openings are scheduled for September 2026, with Athens, Birmingham, and Bessemer receiving new locations. The program will continue licensing and opening new sites toward its target of at least 37 statewide dispensaries. The Alabama Medical Cannabis Commission (AMCC) will oversee further expansion rounds and compliance monitoring.
Sam Blakemore, chair of the AMCC, emphasized the expansion’s importance: “Having more dispensary locations throughout the state is vital for patient access and affordability.” Vince Schilleci, owner of Callie’s Apothecary, noted that additional locations ease the burden on patients who have faced travel barriers, stating: “We’re just happy to now have multiple locations in the state to make it a little bit easier for those patients that are having to travel.”, as first reported by the Alabama Reflector